

**SMS Lifesciences India Limited****Registered & Corporate Office :**

Plot No. 19-III, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.
Tel : +91-040-6628 8888, Fax : +91-40-2355 1401
CIN : L74930TG2006PLC050223
Email : info@smslife.in, Website : www.smslife.in

July 14, 2025

To

BSE Limited,

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code: 540679

Through: BSE Listing Center

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Trading Symbol: SMSLIFE

Through: NEAPS Portal

SUB: INVESTOR PRESENTATION (Q4-FY25)

Ref: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In continuation to financial results submitted on May 29, 2025, we hereby attach the **"INVESTOR PRESENTATION"** for the quarter and year ended March 31, 2025.

Please note that the Statement of Audited Financial Results of the Company for the quarter and year ended March 31, 2025, are already hosted on the website of BSE Ltd, National Stock Exchange of India Limited and available on the website of the Company. [Click here for full results.](#)

Please take the same on record and suitably disseminate it to all concerned.

For SMS Lifesciences India Limited

TVVSN Murthy

Managing Director

DIN: 00465198



SMS LIFESCIENCES INDIA LIMITED

INVESTOR PRESENTATION – Q4 & FY 25

JULY 2025

About the Company

SMS Lifesciences is a global player in Pharmaceutical **APIs/Intermediates** manufacturing having strong research and manufacturing team supported by state of the art facilities accredited by USFDA, Japan PMDA, WHO GMP apart from other global regulatory authorities. The Company is operating since 1990, with Corporate office in Hyderabad, manufacturing facilities in Hyderabad and Vizag & research facilities in Hyderabad. SMS Lifesciences caters to leading generic and innovator customers globally. Company won accolades like **“India Pharma Bulk Drug Company of the Year Award”** from Government of India in 2020 and **“Outstanding Export Performance Award 2018-19”** in “All round-Rising Star” Category from the Pharmaceuticals Export Promotion Council of India.

REGULATORY ACHIEVEMENTS



DSIR



Journey so far...

2006

Incorporation

The Company was officially incorporated

2016

Acquisition

Company was acquired by SMS Pharma as a wholly owned subsidiary.

2017

Demerged

2 manufacturing facility were vested with Company vide NCLT demerger order dated May 15, 2017

2018

Acquired Mahi Drugs

Acquired Mahi Drugs Private Limited with a 100% stake.

2022

Diluted stake in Mahi

Diluted stake to 60% in Mahi Drugs by infusing Foreign Direct Investment (FDI).

SUCCESSFUL USFDA AUDIT MILESTONES



No observations during the Audit
Unit 1, Kazipalli

2022



Audit revealed one procedural
observation
Manufacturing plant at Kazipalli

May 2025

2018

Unit 1 located at Kazipalli

Conducted with one observation.



January 2025


Manufacturing plant of Mahi
Drugs (subsidiary) at Vizag

Successfully audited with no
observation



USFDA inspections are in-line with the long term goals of the Company.

BUSINESS UPDATE



Stable Revenues

Consistent income in SMS Life from Ranitidine and Famotidine

Project Execution

Successful intermediate project for a large customer in USA.

API Additions

Integration of 5+ APIs each in SMS Life & Mahi Drugs.

Commercialization New Projects Start

Contract manufacturing projects in SMS Life & Mahi Drugs.

USFDA filings in FY26 in Mahi Drugs (subsidiary)

CAPEX UPDATE

API Line Expansion

Completion of a new API line expansion & will be operational from Q3FY26

Capacity Expansion

Expansion of capacity in Unit 4

Effluent System Upgrade


Increase in capacity of effluent treatment systems in Unit 1 & 4

Unit 1 Renovation

Capacity expansion & Renovation of a major production block in Unit 1

New API Line Addition

Addition of a new API line in Mahi drugs by FY27



REGULATORY MILESTONES

Upcoming ANVISA Inspection


Scheduled ANVISA (Brazil) inspection
in SMS Life (Unit 1) in Sep 2025

USFDA Inspection in SMS Life (Unit 1)


Successful inspection by
USFDA in May 2025

USFDA Inspection in Mahi Drugs

Successful inspection by
USFDA in January 2025



Key Strategic Focus



Q4 & FY25 PERFORMANCE

Performance Highlights (Standalone)

₹ in lakhs

Particulars	Q4F25	Q4F24	YoY	Q3F25	QoQ	FY25	FY24	YoY
Revenue from Operations	8,542.78	8,637.37	-1.10%	8,287.65	3.08%	33,337.10	30,000.16	11.12%
Cost of goods sold	5,890.91	6,144.35	-4.12%	5,471.97	7.66%	22,466.68	21,269.51	5.63%
Gross profit	2,651.87	2,493.02	6.37% ↑	2,815.68	-5.82% ↓	10,870.42	8,730.65	24.51% ↑
<i>% to Revenue</i>	<i>31%</i>	<i>29%</i>		<i>34%</i>		<i>33%</i>	<i>29%</i>	
EBITDA	779.68	1,309.24	-40.45% ↓	1,312.89	-40.61% ↓	4,817.73	3,826.81	25.89% ↑
<i>% to Revenue</i>	<i>9%</i>	<i>15%</i>		<i>16%</i>		<i>14%</i>	<i>13%</i>	
Other Income	219.95	227.87	-3.48%	6.13	3488.09%	394.56	383.68	2.84%
PBT	333.41	790.82	-57.84% ↓	860.97	-61.28% ↓	3,004.11	1,911.23	57.18% ↑
<i>% to Revenue</i>	<i>4%</i>	<i>9%</i>		<i>10%</i>		<i>9%</i>	<i>6%</i>	
PAT	267.51	593.33	-54.91% ↓	622.75	-57.04% ↓	2,137.08	1,306.54	63.57% ↑
<i>% to Revenue</i>	<i>3%</i>	<i>7%</i>		<i>8%</i>		<i>6%</i>	<i>4%</i>	

Profitability in Q4 has declined as compared to previous quarters due to Provision for Doubtful Debts amounting to ₹4.34 cr.

Performance Overview (standalone)

Key financial metrics and year-over-year as well as quarter-over-quarter comparisons fro Q4FY25 & FY 25



₹85.43 cr

Q4F25 Revenue

Revenue from operations in Q4FY25

-1.1%

YoY Revenue Change

Year-over-year decline in Q4 revenue

₹333.37 cr

FY25 Revenue

Total revenue from operations in FY25

63.57%

FY25 PAT Growth

Profit after tax growth compared to FY24

₹4.34 cr

Provision Impact

Provision for doubtful debts lowering Q4 EBITDA

₹2.67 cr

Q4F25 PAT

Profit after tax in Q4FY25

Performance Highlights (consolidated)

₹ in lakhs

Particulars	Q4F25	Q4F24	YoY	Q3F25	QoQ	FY25	FY24	YoY
Revenue from Operations	8,911.24	8,999.15	-0.98%	8,460.10	5.33%	34,472.35	30,595.84	12.67%
Cost of goods sold	5,631.73	6,011.35	-6.32%	5,317.14	5.92%	21,961.05	20,879.26	5.18%
Gross profit <i>% to Revenue</i>	3,279.51 37%	2,987.80 33%	9.76% ↑	3,142.96 37%	4.34% ↑	12,511.30 36%	9,716.58 32%	28.76% ↑
EBITDA <i>% to Revenue</i>	976.11 11%	1,372.12 15%	-28.86% ↓	1,281.19 15%	-23.81% ↓	4,989.92 14%	3,494.10 11%	42.81% ↑
Other Income	233.94	236.21	-0.96%	5.74	3975.61%	486.01	382.81	26.96%
PBT <i>% to Revenue</i>	392.85 4%	710.19 8%	-44.68% ↓	691.71 8%	-43.21% ↓	2,618.99 8%	984.66 3%	165.98% ↑
PAT <i>% to Revenue</i>	348.27 4%	647.48 7%	-46.21% ↓	485.30 6%	-28.24% ↓	1,873.24 5%	632.77 2%	196.04% ↑

Profitability in Q4 has declined as compared to previous quarters due to Provision for Doubtful Debts amounting to ₹4.34 cr.

Performance Overview (Consolidated)

Key financial metrics and year-over-year as well as quarter-over-quarter comparisons fro Q4FY25 & FY 25



₹89.11 cr

Q4F25 Revenue

Revenue from operations in Q4FY25

-0.98%

YoY Revenue Change

Year-over-year decline in Q4 revenue

₹344.72 cr

FY25 Revenue

Total revenue from operations in FY25

196.03%

FY25 PAT Growth

Profit after tax growth compared to FY24

₹4.34 cr

Provision Impact

Provision for doubtful debts lowering Q4 EBITDA

₹3.48 cr

Q4F25 PAT

Profit after tax in Q4FY25

Other Points of Interest

Key updates regarding audit, dividends, and name change proposal.

1 Dividend Declaration

The Board announced a ₹1.50 dividend per equity share for FY 2024-25, subject to approval of shareholders. .


2 Name Change Proposal

The Board approval for changing the name of the Company to 'HALEOS LABS LIMITED', subject to necessary approvals.

3 Reappointment of Executive Director

The Board approved the reappointment of Mr. TV Praveen as Executive Director for 3 years, subject to approval of shareholders.

Geographical Break-up




Company majorly exported to China, Indonesia, USA, Malaysia, Singapore, Spain, Brazil.

Historical Performance (Standalone)

₹ in lakhs

Revenue




Profit before Tax



Cash profit



E P S




Exceptional income in FY22 & FY 23 of ₹1,270 lakhs & ₹235 lakhs respectively.

Historical Performance (Consolidated)

₹ in lakhs

Revenue




Profit before Tax



Cash profit



E P S



Exceptional income in FY22 & FY 23 of ₹1,270 lakhs & ₹235 lakhs respectively.

Factory - Unit 1 (Aerial View)



Built-up Area: 13619.87 Sq.M

Green Belt Area: 15,248 Sq.M

Plant Area: 47,581.62 Sq.M

Research & Development



DSIR approved facility for Research & Development located at Sanath Nagar, Hyderabad

Company has spent ₹630 lakhs in the year 2024-25 (i.e. 2% of the turnover)

70 member highly skilled team along with scientists, driving innovation across key focus areas

During the last year, 7 DMFs were filed with USFDA for SMSLIFE & Mahi

Process / Analytical method development of APIs and intermediates

Focus on Novel route synthesis, Process Robustness, Cost effectiveness, and Technology Transfer

Mahi Drugs Pvt. Ltd. (Subsidiary)



Established in the year 2012 and was acquired by Company as Wholly-owned subsidiary in 2018

Located in J.N Pharma City, Parawada, Anakapalli District, Andhra Pradesh, India

World class Infrastructure and Plant design by considering QBD


2 API lines & 4 Intermediate blocks (213 KL)

Can handle batch sizes ranging from 500 grams to 1000 Kg.

Storage facilities for CRT (20-25 °C), Freezer (-20 °C) & Refrigerator (2-8 °C)

Successfully inspected by USFDA in January 2025.

Supported by Comprehensive Chemicals and Process Capabilities...



- Can maintain minimum temperature of -70°C and maximum temperature of 220°C , at pressures up to 25kgs in the reactor while manufacturing various products in our plant.
- Capable to perform High vacuum distillation at vacuum levels of 0.1 Torr.
- Experience in handling the diverse chemical reactions for various APIs and Intermediates of different therapeutic categories to human consumption manufactured on site.

Board of Directors



Mr. TVVSN Murthy
Managing Director



Mr. TV Praveen
Executive Director



Mrs. Sudeepthi Gopineedi
Whole-time Director



Dr. (Mr.) Srinivas Samavedam
Independent Director



CA. Mr. P. Sarath Kumar
Independent Director



Dr. (Mr.) Mannam Malakondaiah
Independent Director



CA. (Mrs.) Sundaramma Patibandla
Women Independent Director

Brief profile of the Board members are available on the website of the Company.

Awards /Accolades



- Received the **“Outstanding Export Performance Award 2018-19”** in **“All round-Rising Star”** Category from The Pharmaceuticals Export Promotion Council of India.



- Received **“Pharma Bulk Drug Company of the year”** from Govt. of India



Relationships with Marquee Clients



THANK YOU



Company

SMS Lifesciences India Limited

CIN: L74930TG2006PLC050223

Mr. Trupti Ranjan Mohanty, Compliance Officer

 : cs@smslife.in |  : www.smslife.in

Share Transfer Agents

M/s. Aarthi Consultants Private Limited

Mr. Jagan Mohan Gobburi, Compliance Officer

1-2-285, Domalguda, Hyderabad-500 029, Telangana State

 : info@arthiconsultants.com |  : 276381111, 27642217, 27634445